Unraveling the Abbreviated Development Path

Publication of the Public Consultation for the review of RDC 200 - what is new?

NEW REGULATORY FRAMEWORK OF API

INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200

COVID-19: What facilities is ANVISA providing at this time of crisis?

Why are 24% of drug registrations still rejected?

Cannabis: challenges and opportunities

NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?

Publication of the new API regulatory framework: what is essential to know?

What is important about the new regulatory framework for good manufacturing practices?

Cannabis for therapeutic uses: is this a new market?

DDCM: what are the points that generate the most demands at ANVISA (Part 2)?

New rules for outsourcing in the pharmaceutical industry: many possibilities!